Viva Biotech Holdings is a Shanghai-based company that specializes in structure-based drug discovery services for biotechnology and pharmaceutical clients worldwide. Founded in 2008, the company offers a comprehensive range of research and development services, including fragment-based drug discovery and advanced screening technologies such as affinity selection mass spectrometry and cryo-electron microscopy. Viva Biotech provides various products, including cell lines, crystal structures, GPCR proteins, and antibodies, alongside services in medicinal chemistry, in vitro pharmacology, and antibody discovery. The company operates as an integrated drug discovery platform, combining its expertise in early-stage drug research with contract development and manufacturing services for small molecule active pharmaceutical ingredients and intermediates. Its innovative approach and advanced technological platforms position Viva Biotech as a valuable partner in the global drug development landscape.
Eubulus is an early-stage company focusing on building a platform technology for therapeutic enhancement. The company specializes in Proteolysis- targeting chimeras (PROTACSs).
Totient
Seed Round in 2020
Totient Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2016. It specializes in data analysis for drug discovery and development, focusing on identifying novel tissue-specific antigens using tertiary lymphoid structures (TLSs). The company employs advanced machine learning and immunoinformatics to extract valuable insights from large datasets, facilitating the rapid assembly of high-affinity antibody candidates. Totient's platform is versatile, enabling the development of therapeutics aimed at treating cancer, autoimmune diseases, infections, and viral conditions. By leveraging knowledge from recent research and patient-derived tissues with exceptional immune responses, Totient aims to deliver effective antibody therapeutics for a range of medical applications.
Triumvira Immunologics
Series A in 2020
Triumvira Immunologics is an immunotherapy company founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada. The company focuses on developing innovative T cell therapies for cancer treatment, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Its lead product, CD19-TAC01, targets CD19 for the treatment of B cell malignancies. Triumvira's proprietary T cell Antigen Coupler (TAC) technology enhances the recruitment of the natural T cell receptor and operates independently of the major histocompatibility complex. This unique approach enables the creation of more effective therapies for a diverse range of patients suffering from both solid and liquid tumors, as well as other diseases.
Regenacy Pharmaceuticals
Series A in 2020
Regenacy Pharmaceuticals, LLC is a biopharmaceutical company based in Boston, Massachusetts, founded in 2016. The company focuses on developing innovative treatments for peripheral neuropathies, hemoglobinopathies, and certain oncology indications. Its approach centers on the regeneration of normal protein function through the use of oral, isoform-selective histone deacetylase (HDAC) inhibitors. Notably, Regenacy is advancing the selective HDAC6 inhibitor ricolinostat, which has potential applications in treating sickle cell disease and beta-thalassemia. Through its novel, disease-modifying strategies, Regenacy aims to address significant unmet medical needs in these therapeutic areas.
DTx Pharma
Series A in 2020
DTx Pharma, LLC is a biotechnology company focused on developing and commercializing fatty acid-conjugated peptide therapeutics for patients with rare and chronic diseases. The company specializes in RNA-based therapeutics, utilizing a delivery technology platform that enhances the distribution of nucleic acid drugs to various tissues and organ systems beyond the liver. This innovative approach addresses limitations associated with previous-generation RNA delivery methods, such as poor pharmacokinetics and inadequate cellular uptake. DTx Pharma's products target conditions including retinitis pigmentosa, Duchenne muscular dystrophy, and central nervous system disorders. Founded in 2017 and based in San Diego, California, DTx Pharma aims to provide personalized treatment options across multiple therapeutic areas.
AcuraStem
Convertible Note in 2019
AcuraStem Inc is a biotechnology company, founded in 2016 and based in Monrovia, California, that focuses on developing a precision medicine platform aimed at addressing Amyotrophic Lateral Sclerosis (ALS). The company utilizes complex cellular models derived from ALS patients to evaluate disease progression and test existing FDA-approved therapeutics and their combinations. By employing advanced cellular reprogramming and artificial intelligence technologies, AcuraStem seeks to transform the standard of care for neurodegenerative diseases, enabling drug discovery companies to assess their therapeutic candidates more effectively. The team comprises experts, including PhDs, professors, and experienced professionals from the pharmaceutical industry, all dedicated to finding innovative treatments for this challenging health issue.
Mebias Discovery
Venture Round in 2019
Mebias Discovery, LLC is a pharmaceutical company focused on discovering and developing pathway-selective drugs that target G-protein coupled receptors (GPCRs). Founded in 2015 and based in Philadelphia, Pennsylvania, Mebias aims to create next-generation GPCR drugs that minimize on-target side effects traditionally associated with these therapies. The company utilizes a validated drug discovery platform to identify molecules that can selectively bind to GPCRs, which may lead to improved treatment options for a range of conditions, including neurodegenerative disorders, mood disorders, non-opioid pain management, cardiovascular diseases, and immuno-oncology. By employing this innovative approach, Mebias Discovery seeks to reduce the risks commonly associated with conventional drug development methods, thus providing new therapeutic avenues for various health issues.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.